Tuberculosis among HIV-positive patients: an international prospective observational study

Newsletter May 2012

TB:HIV Study Update:

Currently, there are 437 patients enrolled in the TB:HIV Study. The first follow-up data have now been collected on 143 patients.  Many thanks to all study investigators for their excellent work and contribution to the study. If you have not submitted follow-up forms yet, or have any questions, please contact Anne Marie ( ) as soon as possible. The next round of follow-up will be at the end of May 2012.  

The Coordinating Centre will collect the following data during summer 2012:

Enrolment – on HIV-infected patients diagnosed with active TB during 1.01.2012 – 1.07.2012

6-month follow-up on HIV-infected patients diagnosed with active TB during 1.07.2011 – 1.01.2012

12-month follow-up on HIV-infected patients diagnosed with active TB during 1.01.2011 – 1.07.2011

The purpose of the follow-up is to:

Verify data already in-house (provided at enrolment, pre-printed on the forms). This step remains important – please verify the data are high quality which is crucial for the data analysis

Collect additional follow-up data on TB disease and underlying HIV-infection (all available information from last reported and up to date)

Third Party Agreement:

All participating sites need to sign the Third Party Agreement with Coordinating Centre (CHIP) in order to be able to receive financial reimbursement through the EuroCoord funding for their contribution. CHIP has circulated the Third Party Agreement earlier – and sites that did not yet submit a signed agreement to CHIP have received a new mail with all agreement documents on 14 May 2012. Please contact our Director of Administration Jesper Grarup ( as soon as possible if you have any questions to the Agreement or for any reason have not received it.

Mycobacterial samples:

We are very pleased to announce that we have received the first Mycobacterial samples at the Coordinating Centre. Collection of such samples provides a unique feature of our collaboration and will enable centralized laboratory analysis of genetic profiles and resistance. Please contact Daria ( regarding arrangements of sample shipment or for any details regarding Mycobacterial sample collection. You will be reimbursed 30 Euro for each included sample, and shipment costs will be covered by CHIP.

Plasma samples:

A new substudy of the TB:HIV Study is collection of plasma samples in HIV-infected patients during TB disease with the purpose of studying biomarkers in TB/HIV coinfected patients. Plasma samples should be collected three times during the course of TB disease:  at the time of TB diagnosis, 2, and 6 months after TB diagnosis.

If you may be interested in participating in this substudy, please indicate your interest by no later than June 15th, 2012. If you have plasma samples stored on patients already enrolled in the TB:HIV study, it is also possible to contribute these to the study. Please contact us for more detailed information or in case of questions. Plasma samples will be reimbursed with 5 Euro each and shipment costs will be covered by CHIP.

TB:HIV Study Group
Central Northern Europe:
Denmark (Danish HIV Cohort)
France (Aquitaine Cohort)    
Switzerland (Swiss HIV Cohort)   
United Kingdom: Cardiff, Leicester, London, Manchester, Sheffield
Southern Europe:
Italy: Bari, Brescia, Genova, Monza, Palermo, Rome, Sanremo
Spain: Barcelona, Madrid, San Sebastián
Latin America:
Argentina: Buenos Aires
Brazil: São Paulo, Vitória
Chile: Santiago
México: México
Peru: IMPACTA    
Eastern Europe
Belarus: Gomel, Minsk, Svetlogorsk
Estonia: da-Viru county
Latvia: Riga
Lithuania: Vilnius
Poland: Bialystok, Warsaw, Wroclaw
Romania: Bucharest
Russia: Novgorod the Great
St. Petersburg

Update from EuroCoord
Please find the latest EuroCoord newsletter at

TB:HIV Study Coordinating Centre: Copenhagen HIV Programme, University of Copenhagen, Faculty of Health Sciences, The Panum Institute/Building 21.1, Blegdamsvej 3B, 2200 Copenhagen N, Denmark, Tel: +45 35 45 57 57, Fax: +45 35 45 57 58, e-mail: website: